NCT07062354

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is for people who have head and neck cancer that has come back or spread to other places in the body.

Detailed description

This study is being done to find out if adding amivantamab hyaluronidase to the usual chemotherapy treatment can improve the usual treatment for advanced head and neck cancers.

Conditions

• Head &Amp; Neck Cancer
• Head &Amp; Neck Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)	Carboplatin + Paclitaxel + Amivantamab hyaluronidase

Timeline

• Start date: 2026-03-25
• Primary completion: 2028-10-01
• Completion: 2029-10-01
• First posted: 2025-07-14
• Last updated: 2026-04-09

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study